MedTrace Logo

Extracellular Signal-Related Kinase Biomarker Development in Autism

NCT01850459 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 213

Last updated 2017-04-19

No results posted yet for this study

Summary

The purpose of this research study is to establish a way to help the development of targeted treatments in autism spectrum disorders. This may also help in early diagnosis of autism and may possibly predict severity. The study will compare subject's ERK (extracellular signal-related kinase) signaling to age- and gender-matched neurotypical controls and Intelligence quotient (IQ)-matched developmental disabilities.

Conditions

  • Autism Spectrum Disorders

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Craig A. Erickson, M.D. · Children's Hospital Medical Center, Cincinnati

Eligibility

Min Age
3 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01850459 on ClinicalTrials.gov